Agnes Wold Calls Transgender Care for Minors Ethically Unacceptable Amid Health Authority Warnings

Socialstyrelsen issued a warning in 2022 against puberty blockers and gender hormones for minors, yet prescriptions for these treatments have risen. The debate over gender-affirming care for children in Sweden traces back to a 25-year-old medical experiment at Stockholm’s KID-clinic, which pioneered early transition treatments for youth. The clinic’s approach, influenced by Dutch psychologist Peggy Cohen-Kettenis, began in 1998 with a model that prioritized early intervention over observation, despite limited evidence of long-term safety or efficacy.

What triggered the shift in treatment protocols?

The KID-clinic in Stockholm initially treated only a few children annually, but by 2015, demand surged, leading to the opening of two additional clinics. By 2018, over 800 children were diagnosed with gender dysphoria, though many had co-occurring mental health or social challenges. This contrasted with the original Dutch criteria, which excluded individuals with psychiatric diagnoses or unstable family environments.

Why do experts question the long-term safety of these treatments?

Studies from the Swedish Agency for Health Technology Assessment and Effectiveness (SBU) in 2019 found no scientific evidence that gender-affirming treatments improve mental health or prevent suicide in minors. However, known side effects include bone density loss, infertility, and increased risks of heart disease and blood clots. Flickas who undergo breast removal cannot breastfeed, and boys receiving estrogen face heightened clotting risks.

What are the ethical concerns raised by the medical community?

Experts argue that the lack of long-term data and the inability to distinguish between temporary gender nonconformity and persistent trans identity make early interventions ethically problematic. Socialstyrelsen’s 2022 warning highlighted these risks, yet prescriptions for puberty blockers and hormones have continued to rise, particularly among boys.

What may happen next in Sweden’s approach to youth gender care?

Health officials may face pressure to enforce Socialstyrelsen’s 2022 recommendations, but clinics have continued prescribing treatments. A possible next step is increased regulatory scrutiny or expanded research initiatives. However, the absence of conclusive evidence means outcomes remain uncertain.

How does Sweden’s experience compare to other countries?

Sweden adopted early gender transition protocols in 2001, years before the U.S. and Germany. While other nations delayed clinical adoption, Sweden’s approach became a global reference point. However, the lack of comparative studies has left gaps in understanding long-term outcomes.

Frequently Asked Questions

What triggered the rise in gender-affirming treatments for minors in Sweden? The KID-clinic in Stockholm began treating children for gender dysphoria in 1998, influenced by Dutch psychologist Peggy Cohen-Kettenis’s model of early intervention. By 2018, over 800 children were diagnosed with gender dysphoria, despite initial criteria that excluded those with psychiatric or social challenges.

Why do experts question the safety of puberty blockers and hormones for minors? Studies have shown no evidence that these treatments improve mental health or prevent suicide. Known risks include infertility, bone loss, and increased cardiovascular risks. The Swedish SBU report in 2019 highlighted these concerns, but prescriptions have continued to rise.

What are the ethical implications of early gender transition for children? Critics argue that the inability to distinguish between temporary gender nonconformity and persistent trans identity makes early interventions risky. Socialstyrelsen’s 2022 warning emphasized these concerns, but clinics have not fully adhered to the recommendations.

Could the lack of long-term data on gender-affirming treatments lead to broader policy changes in Sweden?